June is Alzheimer’s and brain consciousness month.
Promising research warning!
If you have television or a screen at all, you have probably heard of glucagon-like peptide-1 (GLP-1) receptor agonists or GLP-1 medication. The popular drugs for weight loss with prescription weight loss help with blood sugar and appetite in people who live with type 2 diabetes and obesity.
GLP-1 drugs were also associated with a reduced risk of cardiovascular events, kidney events and kidney failure. Now the researchers hope to add Alzheimer’s to the list.
A recently carried out study showed that the GLP-1 drug-like embankment (which you may know as Ozempic and Wegovy) can slow down the development of Alzheimer’s or even prevent the disease in people with type 2 diabetes.
“This is an important finding, especially since it was based on real health records of over one million people,” said Babak Tousi, MD, director of clinical studies at the Lou Ruvo Center for Cleveland Cleveland, Ohio.
The study showed that people with type 2 diabetes who took SEMAGLUTID significantly less often 40% to 70%-in which Alzheimer’s was diagnosed within three years, compared to people who take other diabetes medication, including other GLP-1 medication.
“It indicates that Semaglutid may be more than just checking blood sugar – it may offer real brain protection,” said Tousi.
Read: The Skinny on Microdosing GLP-1 medication >>
How Semaglutid affects the health of the brain
Research is continued on the brain in relation to the effects of Semaglutid – and most studies have affected animals so far – but a growing group of studies shows that Semaglutide can benefit from people with diabetes and/or obesity through improved memory, learning and general mental performance.
A systematic review showed that Semaglutid protected the blood-brain barrier, which is responsible for stopping toxins, pathogens (substances that cause diseases) and other harmful substances that go into the brain.
“Semaglutid can calm an inflammation of the brain, especially in the brain’s immune cells referred to in the brain and contribute to protecting the blood-brain barrier to protect what is like a security guard for the brain,” said Tousi. “It also seems to improve blood flow to reduce oxidative stress – a kind of damage that builds up in the brain – and support the function of the brain cell. All of these factors play a role in Alzheimer’s disease.”
Another study showed that Semaglutid reverse the signs of aging in important brain cells that help keep our brain clean, protected and balanced. “Age can cause these cells to behave, which leads to inflammation in the brain and the confusion. Semaglutid took these cells to behave as in younger brains,” said Tousi.
Let’s take our quiz: How much do you know about Alzheimer’s disease? >>
Tousi also found that the study found that Semaglutide -the formation of an astrocyte type -a brain cell that is poisonous -worsens the inflammation and the brain tissue is damaged, a process that can also be seen in Alzheimer’s disease.
This is similar to the results of another study in which it was found that Semaglutid has improved the cognitive skills in mice by performing several functions, one of which reduces the amount of amyloid plaques in the brain. It is believed that Amyloid plaques play a role in Alzheimer’s, and this research suggests that Semaglutid may not only play a role in the prevention of Alzheimer’s, but also improve Alzheimer’s in people who already have it.
Semaglutid for people who are at risk for Alzheimer’s
Type -2 -Diabetes and obesity are both known risk factors for Alzheimer’s disease. In view of the recent knowledge in Human Studies, Semaglutid can be helpful for people who are exposed to Alzheimer’s disease.
“Since Semaglutid seems to help reduce inflammation and protect the brain, there is a growing interest in whether people without diabetes could benefit, especially people with early memory or strong family history of dementia,” said Tousi. “This could signal a future in which a common diabetes medication plays a major role in the health of the brain and even dementia prevention.”
This is particularly important for women and people who were assigned to women at birth (Afab), since Alzheimer’s is more common in women than in men. In about 1 of 5 women, an Alzheimer disease is diagnosed in their life, compared to 1 out of 10 men.
There is currently no healing for Alzheimer’s.
Promising new research on the horizon
On the horizon, there is hope in relation to the role of Semaglutid in preventing or treating Alzheimer’s disease. The results of the first large-scale human study, which show whether Semaglutid, in people with early Disease stages Alzheimer’s, can slow down in people without type 2-diabetes in September.
Read: Should you take a blood test for Alzheimer’s? >>
Tousi said that the study includes a sub -study in which the spine fluid is analyzed to uncover how the medication works in the brain. The study could provide references to the exact mechanism of Semaglutid and guide future treatments.
“It is also worth noting that Alzheimer women affect more than men, and early data indicates that the brain advantages of Semaglutid may be even stronger in women,” said Tousi. “These attempts should help clarify this.”
From their site articles
Related articles related to the web
